MiMedx (MDXG) Q2 2026 earnings review
Surgical Pivot Accelerates as Wound Business Navigates Medicare Reality
MiMedx's Q2 2026 results reflect a tale of two businesses. The legacy Wound segment revenue plummeted 61% YoY as the brutal reality of January's Medicare reimbursement reset took hold. However, the Surgical segment remained resilient, posting 15% YoY growth. With overall revenue down 35% and profitability reversing from +25% Adjusted EBITDA margin a year ago to -13% today, management is buying its way out of the Wound dependency. The $350 million acquisition of Sanara MedTech adds over $100 million in surgical revenue and fundamentally transforms MiMedx into an OR-focused company, masking the organic deterioration of its base business.
🐂 Bull Case
The $350M Sanara acquisition instantly adds scale, combining two highly complementary surgical portfolios. With $100M+ in immediate revenue and a target of >$400M combined by 2027+, this reduces dependence on the highly volatile Medicare Wound market.
Despite the massive YoY decline, Wound volumes grew 22% sequentially from Q1 2026, with revenue up 11% QoQ. Patient migration to Hospital Outpatient Departments (HOPDs) and Wound Care Centers—which carry more favorable economics—is materializing as predicted.
🐻 Bear Case
The margin profile has completely reversed. Gross margins compressed from 81% to 69% YoY, dragging Adjusted EBITDA to a negative $8M. The company is leaning on $40M in aggressive, annualized cost-cuts just to approach breakeven for the year.
The Medicare changes didn't just hit revenue; they are triggering customer distress. Bad debt expense spiked $5M YoY as legacy private office customers struggled to navigate the new $127.14/sq. cm. payment reality.
⚖️ Verdict: ⚪
Neutral. The base Wound business took a severe hit from macro reimbursement changes, destroying organic profitability. However, the aggressive cost-cutting measures and the transformative Sanara M&A offer a credible, albeit high-execution-risk, lifeline to rebuild a high-margin Surgical powerhouse.
Key Themes
Sanara MedTech: Buying an OR Lifeline
Management executed a massive pivot by acquiring Sanara MedTech for $350M (a 46% premium). This unlocks a $4B incremental Total Addressable Market (TAM), adds over 40 field sales reps, and expands MiMedx's presence into 1,450+ active facilities. Sanara brings complementary soft tissue and musculoskeletal assets (CellerateRX, BIASURGE), creating a combined entity expected to exceed $400M in 2027 revenue with an Adjusted EBITDA margin returning above 20%.
Medicare Reset Crushes Wound Care
The macro risk management warned about in 2025 has fully materialized. The January 1 CMS reimbursement reform, which implemented a flat $127.14/sq. cm. rate, drove Wound segment revenue down 61% YoY to $25.1M. While management highlighted a 22% sequential volume recovery as patients migrated to HOPDs, the structural pricing power of this segment has been permanently altered.
Surgical Segment Remains Stable and Growing
In stark contrast to Wound, the Surgical segment delivered a stable 15% YoY growth to $39.3M, driven by AMNIOFIX and AMNIOEFFECT. This segment now accounts for 61% of total Q2 revenue, up from roughly 34% a year ago. It acts as the organic growth engine while the company digests the Sanara integration.
Rapid Margin Compression and Cash Burn
The loss of high-margin Wound revenue caused gross margins to reverse violently, falling from 81.1% in 25Q2 to 69.0% in 26Q2. Adjusted EBITDA dropped from a record $24.2M profit to an $8.1M loss. Management initiated a restructuring to carve out $40M in annualized expenses, recording a $4M restructuring charge in the quarter. Execution on these cuts is critical to returning to profitability.
Customer Credit Distress Undermining "Recovery" Narrative
Management highlighted a sequential recovery in Wound volumes as evidence that the market is stabilizing. However, a hidden red flag contradicts this rosy view: SG&A explicitly rose due to a $5M spike in bad debt expense tied to the credit deterioration of legacy private office customers. The volume may be shifting, but former core customers are actively failing.
Unlocking New Regulatory Pathways
Innovation continues despite the top-line noise. MiMedx submitted its first two 510(k) applications to the FDA for Placental ECM Particulate and Antimicrobial Xenograft products. Securing 510(k) clearance is a major step toward unlocking new indications, formalizing claims, and diversifying beyond traditional Section 361 tissue pathways.
Other KPIs
Reversing significantly from a positive $14.4M in Q2 2025. The rapid deterioration in profitability and the cash drag of restructuring costs have temporarily suspended the company's strong cash generation narrative.
Total cash ended at $135.8M. While the current balance sheet remains healthy, the Sanara acquisition will be funded via a new $300M senior secured term loan (SOFR + 6.25%). The combined company expects a leverage ratio below 3.0x by year-end 2027, introducing new debt servicing obligations.
The company repurchased 3.5M shares during the quarter under its $100M authorized plan. While supportive of EPS, deploying cash to buybacks while simultaneously taking on $300M in high-yield debt at SOFR+6.25% for M&A warrants scrutiny regarding capital allocation timing.
Guidance
Decelerating aggressively. The midpoint of $275M implies a massive step down from the implied $320M+ run-rate of late 2025. This reflects the permanent rebasing of the Wound segment under the new Medicare reimbursement landscape.
Reversing. Down from a robust ~25% margin in 2025. Reaching breakeven relies entirely on the successful realization of the $40M annualized cost-cutting program implemented in Q2, indicating H2 2026 must swing back to positive profitability.
Accelerating. With the addition of Sanara and the realization of $20M in run-rate synergies, management expects the combined entity to rapidly scale and return to a >20% Adjusted EBITDA margin profile in the first full year post-close.
Key Questions
Sanara Deal Leverage and Timing
You are taking on $300M of debt at SOFR + 6.25% right as the core business flips to negative EBITDA. How much cushion is built into the debt covenants if the $40M in core cost-cuts are delayed or if Wound deterioration accelerates?
Legacy Customer Distress
Bad debt expense spiked by $5M due to legacy private office customers struggling with the new Medicare rates. Are you anticipating further write-downs from this cohort, and how much A/R exposure remains tied to the highest-risk private offices?
Surgical Pricing Power
Surgical grew 15% this quarter. Are you seeing any downstream pricing pressure from hospital VACs (Value Analysis Committees) leveraging the CMS wound pricing cuts to demand discounts on surgical allografts?